UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reynoutria multiflora (Thunb.) Moldenke and its ingredient suppress lethal prostate cancer growth by inducing CDC25B-CDK1 mediated cell cycle arrest

Bioorganic chemistry, 2024-11, Vol.152, p.107731, Article 107731

2024

Volltextzugriff (PDF)

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends

Cancer management and research, 2024-09, Vol.16, p.1267-1283

2024

Volltextzugriff (PDF)

Extrachromosomal circular DNA-related SPOCK1 contributes to development and enzalutamide resistance of prostate cancer by regulating epithelial mesenchymal transition

Heliyon, 2024-09, Vol.10 (18), p.e37075, Article e37075

2024

Volltextzugriff (PDF)

TLK1>Nek1 Axis Promotes Nuclear Retention and Activation of YAP with Implications for Castration-Resistant Prostate Cancer

Cancers, 2024-08, Vol.16 (16), p.2918

2024

Volltextzugriff (PDF)

Editorial: Molecular mechanisms in lethal states of prostate cancer

Frontiers in oncology, 2024-08, Vol.14, p.1475178

2024

Volltextzugriff (PDF)

Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death

Advanced science, 2024-08, Vol.11 (30), p.e2401396-n/a

2024

Volltextzugriff (PDF)

Predictive and Prognostic 18F-Fluorocholine PET/CT Radiomics Nomogram in Patients with Castration-Resistant Prostate Cancer with Bone Metastases Treated with 223Ra

Cancers, 2024-07, Vol.16 (15), p.2695

2024

Volltextzugriff (PDF)

Editorial: New insights into prostate cancer: new biomarkers, molecular mechanisms, and therapeutic approaches

Frontiers in endocrinology (Lausanne), 2024-07, Vol.15, p.1453065

2024

Volltextzugriff (PDF)

PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer

Pharmacological research, 2024-07, Vol.205, p.107234, Article 107234

2024

Volltextzugriff (PDF)

Enzalutamide Prolonged the Duration of Drug Use in Comparison to Abiraterone Acetate and Cabazitaxel after Upfront Docetaxel: A Large Japanese Database Study

Diseases, 2024-07, Vol.12 (7), p.162

2024

Volltextzugriff (PDF)

Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer

Endocrine-related cancer, 2024-07, Vol.31 (7)

2024

Volltextzugriff (PDF)

Reciprocal regulation between RACGAP1 and AR contributes to endocrine therapy resistance in prostate cancer

Cell communication and signaling, 2024-06, Vol.22 (1), p.1-15, Article 339

2024

Volltextzugriff (PDF)

Preclinical evidence for the use of anti‐Trop ‐2 antibody‐drug conjugate Sacituzumab govitecan in cerebral metastasized castration‐resistant prostate cancer

Cancer medicine (Malden, MA), 2024-06, Vol.13 (12), p.e7320-n/a

2024

Volltextzugriff (PDF)

Combination of miR-99b-5p and Enzalutamide or Abiraterone Synergizes the Suppression of EMT-Mediated Metastasis in Prostate Cancer

Cancers, 2024-05, Vol.16 (10), p.1933

2024

Volltextzugriff (PDF)

Cyclin‐dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration‐resistant prostate cancer

Clinical and translational medicine, 2024-05, Vol.14 (5), p.e1678-n/a

2024

Volltextzugriff (PDF)

Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer

Cells (Basel, Switzerland), 2024-04, Vol.13 (8), p.673

2024

Volltextzugriff (PDF)

Updates on Overcoming Bicalutamide Resistance: A Glimpse into Resistance to a Novel Antiandrogen

ACS pharmacology & translational science, 2024-04, Vol.7 (4), p.905-914

2024

Volltextzugriff (PDF)

MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC

Journal of nanobiotechnology, 2024-04, Vol.22 (1), p.145-145, Article 145

2024

Volltextzugriff (PDF)

Sequenztherapie des kastrationsresistenten Prostatakarzinoms: Evidenzbasierte klinische Algorithmen

Aktuelle Urologie, 2024-04, Vol.55 (2), p.161-173

2024

Volltextzugriff (PDF)

Reducing TR4 gene expression enhances the sensitivity of prostate cancer cell lines to olaparib by inhibiting the ATM/ATR pathway

Journal of men's health (Amsterdam), 2024-03, Vol.20 (3), p.113-120

2024

Volltextzugriff (PDF)

Glycolysis related lncRNA SNHG3 / miR-139-5p / PKM2 axis promotes castration-resistant prostate cancer (CRPC) development and enzalutamide resistance

International journal of biological macromolecules, 2024-03, Vol.260 (Pt 2), p.129635-129635, Article 129635

2024

Volltextzugriff (PDF)

YAP1 Regulates the YAP1/AR/PSA Axis through Autophagy in Castration-Resistant Prostate Cancer and Mediates T-Cell Immune and Inflammatory Cytokine Infiltration

Biomedicines, 2024-03, Vol.12 (3), p.661

2024

Volltextzugriff (PDF)

USP54 is a potential therapeutic target in castration-resistant prostate cancer

BMC urology, 2024-02, Vol.24 (1), p.32-32, Article 32

2024

Volltextzugriff (PDF)

FABP5 can substitute for androgen receptor in malignant progression of prostate cancer cells

International journal of oncology, 2024-02, Vol.64 (2), Article 18

2024

Volltextzugriff (PDF)

1 – 25 von 596

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(526)
Mit Volltextzugriff
(540)

Publikationsform

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(498)
Life Sciences & Biomedicine
(488)
Crpc
(384)
Prostate Cancer
(354)
Humans
(290)
Male
(288)
Oncology
(261)
Castration
(155)
Castration-Resistant Prostate Cancer
(151)
Androgens
(140)
Metastasis
(128)
Urology & Nephrology
(107)
Cancer Therapies
(106)
Prostatic Neoplasms, Castration-Resistant - Drug Therapy
(104)
Metastases
(93)
Tumors
(91)
Androgen Receptor
(89)
Cell Line, Tumor
(85)
Prostatic Neoplasms, Castration-Resistant - Pathology
(84)
Aged
(81)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancers
(37)
The Prostate
(28)
Clinical Genitourinary Cancer
(21)
Frontiers In Oncology
(17)
International Journal Of Molecular Sciences
(14)
Oncotarget
(14)
The prostate/the prostate
(13)
Translational Andrology And Urology
(13)
Urologic Oncology
(13)
Anticancer Research
(12)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Reynoutria multiflora (Thunb.) Moldenke and its ingredient suppress lethal prostate cancer growth by inducing CDC25B-CDK1 mediated cell cycle arrest

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends

Extrachromosomal circular DNA-related SPOCK1 contributes to development and enzalutamide resistance of prostate cancer by regulating epithelial mesenchymal transition

TLK1>Nek1 Axis Promotes Nuclear Retention and Activation of YAP with Implications for Castration-Resistant Prostate Cancer

Editorial: Molecular mechanisms in lethal states of prostate cancer

Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death

Predictive and Prognostic 18F-Fluorocholine PET/CT Radiomics Nomogram in Patients with Castration-Resistant Prostate Cancer with Bone Metastases Treated with 223Ra

Editorial: New insights into prostate cancer: new biomarkers, molecular mechanisms, and therapeutic approaches

PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer

Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer

Enzalutamide Prolonged the Duration of Drug Use in Comparison to Abiraterone Acetate and Cabazitaxel after Upfront Docetaxel: A Large Japanese Database Study

Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer

Reciprocal regulation between RACGAP1 and AR contributes to endocrine therapy resistance in prostate cancer

Preclinical evidence for the use of anti‐Trop ‐2 antibody‐drug conjugate Sacituzumab govitecan in cerebral metastasized castration‐resistant prostate cancer

Combination of miR-99b-5p and Enzalutamide or Abiraterone Synergizes the Suppression of EMT-Mediated Metastasis in Prostate Cancer

Cyclin‐dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration‐resistant prostate cancer

Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer

Updates on Overcoming Bicalutamide Resistance: A Glimpse into Resistance to a Novel Antiandrogen

MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC

Sequenztherapie des kastrationsresistenten Prostatakarzinoms: Evidenzbasierte klinische Algorithmen

Reducing TR4 gene expression enhances the sensitivity of prostate cancer cell lines to olaparib by inhibiting the ATM/ATR pathway

Glycolysis related lncRNA SNHG3 / miR-139-5p / PKM2 axis promotes castration-resistant prostate cancer (CRPC) development and enzalutamide resistance

YAP1 Regulates the YAP1/AR/PSA Axis through Autophagy in Castration-Resistant Prostate Cancer and Mediates T-Cell Immune and Inflammatory Cytokine Infiltration

USP54 is a potential therapeutic target in castration-resistant prostate cancer

FABP5 can substitute for androgen receptor in malignant progression of prostate cancer cells

Suchergebnisse filtern